220 related articles for article (PubMed ID: 30807614)
1. Assessment of N-terminal pro-B-type natriuretic peptide level in screening for atrial fibrillation in primary health care.
Ghazal F; Theobald H; Rosenqvist M; Al-Khalili F
PLoS One; 2019; 14(2):e0212974. PubMed ID: 30807614
[TBL] [Abstract][Full Text] [Related]
2. N-terminal pro B-type natriuretic peptide in systematic screening for atrial fibrillation.
Svennberg E; Henriksson P; Engdahl J; Hijazi Z; Al-Khalili F; Friberg L; Frykman V
Heart; 2017 Aug; 103(16):1271-1277. PubMed ID: 28255099
[TBL] [Abstract][Full Text] [Related]
3. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
[TBL] [Abstract][Full Text] [Related]
4. Clinical and echocardiographic characteristics of individuals aged 75/76 years old with screening-detected elevated NT-proBNP levels.
Al-Khalili F; Kemp-Gudmundsdottir K; Svennberg E; Fredriksson T; Frykman V; Friberg L; Rosenqvist M; Engdahl J
Open Heart; 2020; 7(1):e001200. PubMed ID: 32153793
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation.
Shelton RJ; Clark AL; Goode K; Rigby AS; Cleland JG
Eur Heart J; 2006 Oct; 27(19):2353-61. PubMed ID: 16952921
[TBL] [Abstract][Full Text] [Related]
6. Stepwise mass screening for atrial fibrillation using N-terminal pro b-type natriuretic peptide: the STROKESTOP II study design.
Engdahl J; Svennberg E; Friberg L; Al-Khalili F; Frykman V; Kemp Gudmundsdottir K; Fredriksson T; Rosenqvist M
Europace; 2017 Feb; 19(2):297-302. PubMed ID: 28011798
[TBL] [Abstract][Full Text] [Related]
7. [Changes in NT-proBNP levels in patients with atrial fibrillation related to heart failure].
Pokorná V; Jurkovicová O; Kaluzay J; Stecová A; Pont'uch P
Vnitr Lek; 2010 Aug; 56(8):788-94. PubMed ID: 20845610
[TBL] [Abstract][Full Text] [Related]
8. Elevated admission N-terminal pro-brain natriuretic peptide level predicts the development of atrial fibrillation in general surgical intensive care unit patients.
Chokengarmwong N; Yeh DD; Chang Y; Ortiz LA; Kaafarani HMA; Fagenholz P; King DR; DeMoya M; Butler K; Lee J; Velmahos G; Januzzi JL; Lee-Lewandrowski E; Lewandrowski K
J Trauma Acute Care Surg; 2017 Sep; 83(3):485-490. PubMed ID: 28463935
[TBL] [Abstract][Full Text] [Related]
9. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV
Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349
[TBL] [Abstract][Full Text] [Related]
10. Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation.
Staszewsky L; Meessen JMTA; Novelli D; Wienhues-Thelen UH; Disertori M; Maggioni AP; Masson S; Tognoni G; Franzosi MG; Lucci D; Latini R
BMC Cardiovasc Disord; 2021 Nov; 21(1):553. PubMed ID: 34798808
[TBL] [Abstract][Full Text] [Related]
11. Atrial fibrillation and amino-terminal pro-brain natriuretic peptide as independent predictors of prognosis in systolic heart failure.
Dini FL; Gabutti A; Passino C; Fontanive P; Emdin M; De Tommasi SM
Int J Cardiol; 2010 Apr; 140(3):344-50. PubMed ID: 19128846
[TBL] [Abstract][Full Text] [Related]
12. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Christersson C; Ezekowitz J; Gersh BJ; Hanna M; Hohnloser S; Horowitz J; Huber K; Hylek EM; Lopes RD; McMurray JJ; Granger CB
J Am Coll Cardiol; 2013 Jun; 61(22):2274-84. PubMed ID: 23563134
[TBL] [Abstract][Full Text] [Related]
13. Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study.
Morello A; Lloyd-Jones DM; Chae CU; van Kimmenade RR; Chen AC; Baggish AL; O'Donoghue M; Lee-Lewandrowski E; Januzzi JL
Am Heart J; 2007 Jan; 153(1):90-7. PubMed ID: 17174644
[TBL] [Abstract][Full Text] [Related]
14. Supraventricular arrhythmia, N-terminal pro-brain natriuretic peptide and troponin T concentration in relation to incidence of atrial fibrillation: a prospective cohort study.
Xiao J; Persson AP; Engström G; Johnson LSB
BMC Cardiovasc Disord; 2021 Mar; 21(1):134. PubMed ID: 33711943
[TBL] [Abstract][Full Text] [Related]
15. Blood Biomarkers of Heart Failure and Hypercoagulation to Identify Atrial Fibrillation-Related Stroke.
Kneihsl M; Gattringer T; Bisping E; Scherr D; Raggam R; Mangge H; Enzinger C; Fandler-Höfler S; Eppinger S; Hermetter C; Bucnik B; Poltrum B; Niederkorn K; Fazekas F
Stroke; 2019 Aug; 50(8):2223-2226. PubMed ID: 31216968
[TBL] [Abstract][Full Text] [Related]
16. N-terminal pro brain natriuretic peptide eliminates the prognostic effect of atrial fibrillation in patients with chronic heart failure.
Schnorbach J; Fröhlich H; Täger T; Corletto A; Katus HA; Frankenstein L
ESC Heart Fail; 2019 Aug; 6(4):640-648. PubMed ID: 31259484
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation.
Roldán V; Vílchez JA; Manzano-Fernández S; Jover E; Gálvez J; Puche CM; Valdés M; Vicente V; Lip GY; Marín F
Stroke; 2014 Mar; 45(3):696-701. PubMed ID: 24519407
[TBL] [Abstract][Full Text] [Related]
18. NT-ProBNP predicts rhythm stability after cardioversion of lone atrial fibrillation.
Möllmann H; Weber M; Elsässer A; Nef H; Dill T; Rixe J; Schmitt J; Sperzel J; Hamm CW
Circ J; 2008 Jun; 72(6):921-5. PubMed ID: 18503217
[TBL] [Abstract][Full Text] [Related]
19. SERUM cardiac-specific biomarkers and atrial fibrillation in myotonic dystrophy type I.
Russo V; Rago A; Atripaldi L; Leonardi S; Papa AA; Politano L; Golino P; Potpara TS; Nigro G
J Cardiovasc Electrophysiol; 2019 Dec; 30(12):2914-2919. PubMed ID: 31579995
[TBL] [Abstract][Full Text] [Related]
20. Effects of Atrial Fibrillation Screening According to N-Terminal Pro-B-Type Natriuretic Peptide: A Secondary Analysis of the Randomized LOOP Study.
Xing LY; Diederichsen SZ; Højberg S; Krieger DW; Graff C; Frikke-Schmidt R; Olesen MS; Brandes A; Køber L; Haugan KJ; Svendsen JH
Circulation; 2023 Jun; 147(24):1788-1797. PubMed ID: 37061802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
